Cantargia AB
CANTA.STDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
CAN04 (nadunolimab)
Advanced Solid Tumors
CAN04
Non Small Cell Lung Cancer
Carboplatin
Triple Negative Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAN04 (nadunolimab) | Phase 2 | Advanced Solid Tumors | - | - |
CAN04 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Carboplatin | Phase 2 | Triple Negative Breast Cancer | - | - |
Frequently asked questions
What is in Cantargia AB's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cantargia AB's (CANTA.ST) pipeline across Phase 2. Its lead program is CAN04 (nadunolimab) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cantargia AB's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Cantargia AB (CANTA.ST) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CANTA.ST biotech catalysts?→
Add CANTA.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cantargia AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.